NCT05302011View on ClinicalTrials.gov

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

March 30, 2023

Study Completion Date

June 30, 2023

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200mg i.v. day 1-22-43-64

DRUG

Carboplatin or Cisplatin

Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64

DRUG

Docetaxel

75mg/m2 i.v. day 1-22-43-64

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT05302011 - Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter